Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Tiotropiumbromid (ATC-Code: R03BB04) in der Darreichungsform Inhalationslösung innerhalb des Zeitraumes vom 01.12.2026 bis zum 30.11.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

For the active substance Tiotropium bromide (ATC code: R03BB04) in the dosage form inhalation solution, AOK Niedersachsen offers the following. For the period up to the entry into force of exclusive agreements as a result of a formal procurement procedure in accordance with the provisions of Part 4 of the GWB, the health insurance fund grants rebate agreements to all interested pharmaceutical companies, without a selection decision. The contracts are concluded as part of an “open-house model” and serve as a bridge between the start of generic competition (expiry of patents) and the award of exclusive agreements. The offered agreements are not exclusive; agreements with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. Under the open-house model, uniform conditions apply to all participants. Contract content, terms and access procedures are uniform—individual negotiations generally are not carried out. The contract terms are a maximum of twenty-four months; the earliest contract start date is 01.12.2026. All contracts end at the latest on 30.11.2028, regardless of the date on which the respective contract is concluded. Accession and/or conclusion…

TENDER BRIEF

TENDER DOCUMENTS